Universal reference book for medicines
Product name: Revasil (REVASIL)

Active substance: minoxidil

Type: The drug for the treatment of alopecia in men and women

Manufacturer: PATENT-PHARM (Russia) manufactured by POLYSINTEZ (Russia)
Composition, form of production and packaging
Spray for external use 2%.
1 ml

minoxidil 20 mg

50 ml - bottles (1) - packs of cardboard.

100 ml - bottles (1) - packs of cardboard.


Description of the drug approved by the manufacturer for the printed edition of 2011.


With local application of minoxidil, its stimulating effect on hair growth in people with androgenic alopecia (hair thinning, baldness) was noted.
It improves microcirculation, stimulates the transition of hair cells to the active growing phase, changes the effect of androgens on hair follicles.
Reduces the formation of 5-alpha-dehydrotestosterone (possibly mediated), which plays a significant role in the formation of alopecia.
The best effect is for a small prescription of the disease (no more than 10 years), young patients, the bald spot in the top of the head is no more than 10 cm, and there are more than 100 gun and terminal hair in the center of the bald head.
The appearance of signs of hair growth is noted after 4 or more months of application of the drug.
The onset and severity of the effect may vary in different patients.After discontinuation of the use of Revasil, the growth of new hair is suspended, and within 3-4 months the restoration of the original appearance is possible. The exact mechanism of action of the drug Revasil in the treatment of androgenic alopecia is unknown. Minoxidil is ineffective in case of baldness caused by taking a drug, improper nutrition (iron deficiency (Fe), vitamin A), as a result of hair styling in "tight" hairstyles.

With external use, minoxidil is poorly absorbed through normal intact skin: an average of 1.5% (0.3-4.5%) of the total applied dose enters the systemic circulation.The effect of concomitant skin diseases on the absorption of minoxidil is unknown.

After discontinuation of the drug, approximately 95% of minoxidil, which enters the systemic circulation, is excreted within 4 days.
The profile of the metabolic biotransformation of minoxidil after external application of the Revasil preparation has not been fully studied to the present.
Minoxidil does not bind to plasma proteins and is excreted by the kidneys through glomerular filtration.
Minoxidil does not penetrate the blood-brain barrier.
Excreted mainly with urine.
Minoxidil and its metabolites are excreted by hemodialysis.

For treatment of androgenic alopecia (hair restoration) and stabilization of hair loss in men and women.


For external use only.
Regardless of the size of the treated area, apply 1 ml of the solution with a metering device (7 strokes) 2 times a day to the affected areas of the scalp, starting from the center of the affected area. After application, wash hands. The total daily dose should not exceed 2 ml (the dose does not depend on the size of the affected area).
For men, Revasil is most effective in hair loss on the vertex, for women - with hair loss in the middle part.
Apply Revasil only on the dry skin of the scalp. The solution does not require flushing.
The appearance of the first signs of stimulation of hair growth is possible after applying the drug 2 times a day for 4 months or more.
The onset and severity of hair growth, as well as the quality of the hair, can fluctuate in different patients.
According to individual reports, recovery of the initial appearance can be expected within 3-4 months after discontinuation of treatment.

The duration of treatment is about 1 year on average.


Local side effects: Side effects observed in clinical studies of the drug Revasil, in most cases were dermatitis of the scalp.

Less frequent cases of more severe cases of dermatitis, manifested in the form of redness, flaking and inflammation.

In rare cases, itchy scalp, contact dermatitis, folliculitis, hypertrichosis (unwanted hair growth on the body, including facial hair growth in women), seborrhea.

The use of minoxidil can cause an increase in hair loss during the transition from the resting phase to the growth phase, while the old hair falls out, and new ones grow in their place.
This temporary phenomenon is usually observed after 2-6 weeks after the start of treatment and gradually stops within the next two weeks (the appearance of the first signs of the action of minoxidil).
Systemic side effects (with accidental ingestion of the drug): Dermatological diseases: nonspecific allergic reactions (skin rash, urticaria), edema of the face.

Respiratory system: shortness of breath, allergic rhinitis.

Nervous system: headache, dizziness, vertigo, neuritis.

Cardiovascular system: pain in the chest, fluctuations in blood pressure, palpitations, changes in the rhythm of the heart, swelling.


- hypersensitivity to minoxidil or other components of the drug;

- the age is under 18 years;

- violation of the integrity of the skin, dermatosis of the scalp.

The elderly are older than 65 years.

When pregnant and breast-feeding the drug should not be used.


Contraindicated in children under 18 years.


With caution: the elderly are older than 65 years.


Do not apply the drug to other parts of the body.

Apply Revasil only on the dry skin of the scalp after bathing or wait about 4 hours after applying the drug before bathing.
Do not let your head get wet before 4 hours after application. If you applied the drug with your fingertips, after handling the head, your hands should be thoroughly washed. Wash hair with Revasil is recommended in the usual mode. Hairspray and other hair care products can be used during the period of application of Revasil. Before applying hair care products, first apply the Revasil preparation and wait until the treated area of ​​the skin is completely dry. There is no evidence that hair coloring, perming, or the use of hair softeners can somehow reduce the effectiveness of the drug. However, to prevent possible irritation of the skin of the scalp, you need to make sure that the drug has been completely flushed from the hair and skin of the scalp before applying these chemicals. Before starting treatment with Revasil drugs, patients should undergo a general examination, including the collection and study of medical history. The physician should make sure that the scalp skin is healthy. When systemic side effects or severe skin reactions occur, patients should cancel the drug and consult a doctor.
The composition of the drug Revasil includes ethyl alcohol, which can cause inflammation and eye irritation.
In case of contact with sensitive surfaces (eyes, irritated skin, mucous membranes), rinse the area with plenty of cold water.

Accidental ingestion of Revasil may cause systemic side effects due to the vasodilator properties of minoxidil (5 ml of Revasil contain 100 mg of minoxidil, which is the maximum recommended dose for adults when administered intravenously in the treatment of hypertension).

Signs of an overdose: fluid retention, lowering blood pressure, tachycardia.

Treatment: diuretics may be prescribed to eliminate fluid retention if necessary;
for the treatment of tachycardia - beta-blockers.
To treat arterial hypotension, you should inject intravenously 0.9% solution of sodium chloride.
Do not prescribe symptomatic drugs, for example, norepinephrine and epinephrine, which have excessive cardiostimulating activity.

There is a theoretical possibility of strengthening orthostatic hypotension in patients receiving concomitant treatment with peripheral vasodilators, which, however, did not receive clinical confirmation.
We can not rule out a very slight increase in minoxidil in the blood of patients suffering from hypertension and taking minoxidil inward in the case of simultaneous application of Revasil, although relevant clinical studies have not been conducted.
It was found that minoxidil, when applied externally, can interact with some other drugs for external use.

The simultaneous use of a solution of minoxidil for external use and cream containing betamethasone (0.05%) leads to a decrease in systemic absorption of minoxidil.Simultaneous use of cream containing tretinoin (0.05%) leads to increased absorption of minoxidil.
The simultaneous application of minoxidil to the skin and preparations for external use such as tretinoin and dithranol, which cause changes in the protective functions of the skin, may lead to an increase in the absorption of minoxidil.

The drug is approved for use as a means of OTC.


At a temperature of no higher than 25 В° C.
Keep out of the reach of children.
Shelf life.
4 years. Do not use after expiry date.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!